SCLX Scilex Holding Company
USHealthcareAs of 2026-07-10 16:00
Why SCLX matters now
Scilex Holding Company (SCLX) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.48 with +3.04% on the session and $80.5M in market capitalization; recent performance reads 1-month +100.81% and YTD -38.77%.
The latest financial table shown here is Q1 2026, with revenue of $8.6M, net income of $-43.3M, and EPS of $-6.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.4%.
The latest indexable market news headline is "Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Ji Henry filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.21
P/S
1.87
EV/EBITDA
-0.44
DCF Value
$-47.14
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.0%
Operating Margin
-817.1%
Net Margin
-1239.4%
ROE
190.1%
ROA
-142.9%
ROIC
230.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.6M | $-43.3M | $-6.28 |
| Q4 2025 | $4.8M | $-33.1M | $-3.00 |
| FY 2025 | $30.3M | $-358.7M | $-36.48 |
| Q3 2025 | $10.6M | $-257.2M | $-22.17 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
1.71
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.